1. Home
  2. ANGI vs IPHA Comparison

ANGI vs IPHA Comparison

Compare ANGI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Angi Inc.

ANGI

Angi Inc.

HOLD

Current Price

$5.17

Market Cap

209.5M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$2.05

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANGI
IPHA
Founded
1995
1999
Country
United States
France
Employees
2300
163
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
209.5M
189.5M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
ANGI
IPHA
Price
$5.17
$2.05
Analyst Decision
Buy
Strong Buy
Analyst Count
7
4
Target Price
$17.00
$5.75
AVG Volume (30 Days)
1.5M
127.5K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
1242.86
N/A
EPS
N/A
N/A
Revenue
$736,386,000.00
N/A
Revenue This Year
$3.25
$180.36
Revenue Next Year
$3.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
47.60
N/A
52 Week Low
$4.53
$1.18
52 Week High
$19.42
$2.63

Technical Indicators

Market Signals
Indicator
ANGI
IPHA
Relative Strength Index (RSI) 38.06 59.42
Support Level $4.53 $1.72
Resistance Level $8.03 $2.34
Average True Range (ATR) 0.54 0.21
MACD -0.04 0.07
Stochastic Oscillator 19.72 53.85

Price Performance

Historical Comparison
ANGI
IPHA

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: